Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results.
Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. · 2020
Read Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. by Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7489852.txt.
Introduction
Meltzer and co-authors test if vitamin D status links with COVID-19 test results. The cohort held 489 patients at one center. Each had a vitamin D level drawn in the year before testing.
The relative risk was 1.77 times greater for likely deficient patients than for those with likely sufficient status in this cohort. That gap was statistically significant in the team's analysis. Age, race, and other traits were weighed in the models. Still, a cohort study cannot prove that vitamin D changes infection risk. The authors call for randomized trials to settle the point. Trials could test both broad public steps and targeted help for groups low in vitamin D. The work adds a lead, not a verdict.
Catalog record
| CREATOR | Meltzer DO, Best TJ, Zhang H, Vokes T, Arora V, Solway J. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results By David O. Meltzer, Thomas J. Best, Hui Zhang, Tamara Vokes, Vineet Arora, Julian Solway Published in: JAMA Network Open DOI: 10.1001/jamanetworkopen.2020.19722 ABSTRACT Key Points Question Is vitamin D status, reflecting vitamin D levels and treatment, associated with test results for coronavirus disease 2019 (COVID-19)? Findings In this cohort study of 489 patients who had a vitamin D level measured in the year before COVID-19 testing, the relative risk of testing positive for COVID-19 was 1.77 times greater for patients with likely deficient vitamin D status compared with patients with likely sufficient vitamin D status, a difference that was statistically significant. Meaning These findings appear to support a role of vitamin D status in COVID-19 risk; randomized clinical trials are needed to determine whether broad population interventions and interventions among groups at increased risk of vitamin D deficiency and COVID-19 could reduce COVID-19 incidence. INTRODUCTION Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), often produces severe lower respiratory symptoms and has caused more than 745 000 deaths worldwide.1 One challenge in halting this pandemic is the absence of evidence demonstrating effective pharmacologic interventions to prevent COVID-19. Vitamin D treatment has been identified as a potential strategy to prevent or treat COVID-19.2 Vitamin D treatment has been found to decrease other viral respiratory infections, especially in persons with vitamin D deficiency.3 Vitamin D deficiency is common, affecting nearly half the US population, with higher rates among persons with darker skin or reduced sun exposure, including persons living in higher latitudes in the winter, nursing home residents, and health care workers.4 COVID-19 is more prevalent among African American individuals,5 persons living in northern cities in the late winter,6 older adults,7 nursing home residents,8 and health care workers,9 populations who all have increased risk of vitamin D deficiency.4,10,11,12 Moreover, COVID-19 is less prevalent in pregnant women and children13 and in persons living in Japan,14 in whom rates of vitamin D deficiency are lower.15,16,17 Shelter-in-place orders to reduce the spread of COVID-19 may also decrease sun exposure, potentially increasing needs for vitamin D supplementation.18 Given the low risks and low cost of vitamin D treatment, recent reporting has suggested that vitamin D treatment should be scaled.19,20 Nevertheless, evidence of whether vitamin D deficiency is associated with COVID-19 infection and whether vitamin D treatment may help decrease the burden and spread of COVID-19 is lacking. Using data from the electronic health record at the University of Chicago Medicine (UCM) in Chicago, Illinois, we hypothesized that persons tested for COVID-19 would be more likely to test positive for COVID-19 if they had likely deficient vitamin D levels than if they had likely sufficient vitamin D levels. Because patients may have experienced changes in their vitamin D treatment after their most recent vitamin D level measurement before COVID-19 testing, we combined data on patients’ last vitamin D level before COVID-19 testing and changes in their treatment after that vitamin D level measurement to construct a measure of vitamin D status indicating whether each patient was expected to have a vitamin D level that was deficient, sufficient, or of uncertain sufficiency at the time they were tested for COVID-19. METHODS Participants We obtained data for all 4314 patients tested for COVID-19 at UCM from March 3 to April 10, 2020. We obtained electronic health record data for demographic, comorbidity, laboratory, and medication data within 1 year before the date of their first COVID-19 test. Vitamin D levels and treatments within 14 days of COVID-19 testing were excluded from analyses to avoid possible confounding by potential early manifestations of COVID-19, eg, presenting for health care with symptoms that could lead to testing for and treatment of vitamin D deficiency. Twenty-two patients were excluded from eligibility from the analytic sample because their only vitamin D level measurement occurred within 14 days of COVID-19 testing. This study was approved by the University of Chicago Biological Sciences Division Institutional Review Board with a waiver of consent for use of identifiable data. It was determined that this analysis could not be reliably executed without the use of identifiable data and that it was impracticable to obtain consent from all subjects. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. Measurements All variables were defined based on information from the UCM electronic health record (Epic; Epic Systems). COVID-19 test status was determined by any positive COVID-19 polymerase chain reaction test result, with the Centers for Disease Control and Prevention21 or Viacor22 test used until in-house testing with the test from Roche (cobas) began on March 15, 2020.23 Because of test supply, testing at UCM was limited to persons presenting with potential symptoms of COVID-19 admitted to the hospital or health care workers with COVID-19 symptoms and exposure. Patients were deemed to be vitamin D deficient if their most recent serum vitamin D levels within 1 year before their first COVID-19 tests were less than 20 ng/mL for 25-hydroxycholecalciferol (to convert to nanomoles per liter, multiply by 2.496) or less than 18 pg/mL for 1,25-dihydroxycholecalciferol (to convert to picomoles per liter, multiply by 2.4) and deemed not deficient if their most recent levels were equal to or greater than 20 ng/mL or equal to or greater than 18 pg/mL, respectively.24,25,26,27 Vitamin D treatment was defined by report in the electronic health record of vitamin D either in the patient medication list or prescription orders. Vitamin D3 dosing was defined based on most recent daily dose recorded over the past year excluding the 14 days before testing: none, 1 to 1000 IU or a multivitamin, 2000 IU, or greater than or equal to 3000 IU. Indicators for treatment with vitamin D2 and calcitriol were also included. We accounted for possible changes in patients’ vitamin D treatment after the time of their last vitamin D level by categorizing changes in treatment between the date of the last vitamin D level and 14 days before COVID-19 testing as increased, unchanged, or decreased according to the following ordering: calcitriol was considered the highest treatment category followed in decreasing order by greater than or equal to 3000 IU D3, 2000 IU D3, D2, 1-1000 IU D3 or multivitamin, and no vitamin D. We then combined the data on last vitamin D level measurements with changes in treatment after that last vitamin D level to assign each patient to 1 of 4 categories reflecting their likelihood of being vitamin D deficient at the time of COVID-19 testing: likely deficient (last level deficient and treatment not increased), likely sufficient (last level not deficient and treatment not decreased), and 2 groups with uncertain deficiency (last level deficient and treatment increased, and last level not deficient and treatment decreased). Age, sex, and race/ethnicity were also obtained from the electronic health record and coded as reported in Table 1. We also obtained the most recent data during the study period up to 14 days before COVID-19 testing to calculate body mass index and the following International Statistical Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)–based Elixhauser comorbidity clusters28 potentially related to COVID-19 and/or vitamin D metabolism: hypertension,